Moderators: StockLogistics
Search This Board: 
Created: 08/26/2011 12:41:58 PM - Followers: 101 - Board type: Free - Posts Today: 0
VistaGen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. Our CNS portfolio includes three differentiated drug candidates, PH94B, PH10 and AV-101, each with a novel mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential for multiple indications.

Company WebsiteVistaGen Therapeutics, Inc. (VTGN)                                                                                               Press ReleasesPress Releases :: VistaGen Therapeutics, Inc. (VTGN)

FinancialsAll SEC Filings :: VistaGen Therapeutics, Inc. (VTGN)                                                                                 Leadership TeamLeadership :: VistaGen Therapeutics, Inc. (VTGN)

Current Stock PriceQuote :: VistaGen Therapeutics, Inc. (VTGN)                                                                               

 

Pipeline

Our CNS pipeline includes three differentiated new generation CNS drug candidates with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of our drug candidates, PH94B, PH10 and AV-101, has a novel mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential for multiple indications in large mental health and neurology markets.

PH94B Neuroactive Nasal Spray

PH94B is an innovative investigational synthetic neuroactive pherine nasal spray with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with benzodiazepines. PH94B’s rapid-onset mechanism of action is fundamentally different from benzodiazepines and all other FDA-approved anti-anxiety medications. Developed from proprietary compounds called pherines and administered at non-systemic microgram doses as an odorless nasal spray, PH94B binds to nasal chemosensory receptors which activate neural circuits in the limbic amygdala that suppress fear and anxiety. Following a highly statistically significant (p=0.002) Phase 2 study of PH94B in adults with social anxiety disorder (SAD), and a successful meeting with the U.S. Food and Drug Administration (FDA), we are currently preparing for pivotal Phase 3 development of PH94B for the acute treatment of anxiety in adults with SAD.

The FDA has granted Fast Track designation for development of PH94B for SAD, the first such designation ever granted by the FDA for a SAD drug candidate. In a manner analogous to a rescue inhaler used before an asthma attack, PH94B has potential to be used by a person with SAD before an anxiety-provoking stressor.

Based on the results of Phase 2 studies, PH94B has the potential to be the first FDA-approved acute (on-demand) treatment of anxiety for millions who suffer from SAD. In addition, PH94B has potential in postpartum anxiety, preoperative anxiety, PTSD, panic disorder, and generalized anxiety disorder.

PH10 Neuroactive Nasal Spray

PH10 is a synthetic investigational neuroactive pherine nasal spray with a novel, rapid-onset mechanism of action that is fundamentally different from all current treatments for depression. Developed from proprietary compounds called pherines and administered at microgram doses as an odorless nasal spray, PH10 binds to nasal chemosensory receptors which activate neural circuits in the brain that produce antidepressant effects. Specifically, a microgram level dose of PH10 (6.4 mcg) engages specific nasal chemosensory neurons (NCNs). NCNs activate olfactory bulb neurons (OBNs) on the base of the brain. OBNs send neural connections to neurons in the central limbic amygdala, the brain center where mood is regulated. Neurons in the limbic amygdala stimulate release of excitatory neurotransmitters (glutamate, norepinephrine) resulting in rapid-onset antidepressant effects. Systemic uptake and distribution are not required to produce rapid-onset antidepressant effects. In a small exploratory randomized, double-blind, placebo-controlled Phase 2A clinical study in major depressive disorder (MDD), at a 6.4 mcg dose, rapid-onset antidepressant effects were observed and sustained for 8 weeks (p=0.022), without psychological side effects or safety concerns associated with ketamine-based therapy.

AV-101, an Oral NMDAR Glycine Site Antagonist

AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA (N-methyl-D-aspartate) glutamate receptor modulators. The NMDA receptor is a pivotal receptor in the brain and abnormal NMDA function is associated with multiple CNS diseases and disorders, including MDD, epilepsy, levodopa-induced dyskinesia, neuropathic pain and many others. AV-101 is an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), which binds uniquely at the glycine site of the NMDA receptor and has potential to be a new treatment for multiple CNS indications involving NMDA receptors, each with high unmet need.

Recent discoveries from successful AV-101 preclinical studies demonstrate a multi-fold concentration increase in the brain of AV-101 prodrug, and, more importantly, of 7-Cl-KYNA, AV-101's active metabolite, when AV-101 is administered adjunctively with probenecid, a safe and well-known oral anion transport inhibitor used to treat gout. This data suggest that it may be possible to increase therapeutic concentrations and duration of 7-Cl-KYNA in the brain, and thus increase NMDAR antagonism in patients when AV-101 and probenecid are combined.

VistaGen Investor Contact
Mark McPartland
VistaGen Therapeutics
Phone: (650) 577-3606

EmailIR@vistagen.com
 

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#4822
Positive news just hit a few minutes ago,sooner trendzone 09/19/2022 08:38:09 AM
#4821
Yes, hopefully there will be some news/updates soon. Arnold25764 09/01/2022 12:38:41 PM
#4820
Company needs to put news out. ildonaldo 09/01/2022 11:41:00 AM
#4819
Big Gap to fill up top. Arnold25764 09/01/2022 11:37:37 AM
#4818
Taking wall out! ildonaldo 08/31/2022 12:53:58 PM
#4817
Nope. Wishful thinking… ildonaldo 08/30/2022 05:38:22 AM
#4816
They said that last week too.. it’s going Odiwon 08/29/2022 01:32:16 PM
#4815
Bottom is in. Load zone ildonaldo 08/26/2022 03:46:05 PM
#4814
I can see this break $1 plus soon. ildonaldo 08/26/2022 03:45:27 PM
#4813
Agreed. At some point it can’t be held Odiwon 08/23/2022 09:17:04 AM
#4812
A sign that there is a large amount trendzone 08/23/2022 08:01:41 AM
#4811
Another insider purchase.. Only a matter of time Odiwon 08/22/2022 05:36:18 PM
#4810
They are playing with this stock left and Odiwon 08/22/2022 01:38:22 PM
#4809
Lol no doubt.. Odiwon 08/22/2022 09:47:11 AM
#4808
Let's hope they buy this back up to PStockPickz 08/22/2022 09:25:53 AM
#4807
Right this is precautionary and them trying to Odiwon 08/22/2022 09:24:44 AM
#4806
100% agree. Plus we wouldn't see a split PStockPickz 08/22/2022 09:15:28 AM
#4805
It’s not coming , it’s being voted on. Odiwon 08/22/2022 07:54:28 AM
#4804
Sht. Reverse Split coming in news this m1ocha 08/22/2022 07:31:32 AM
#4803
All bollinger bands now below all SMA’s, hoping StockLogistics 08/21/2022 10:23:18 PM
#4802
What we thinking for next week. I’m pretty Odiwon 08/21/2022 06:46:30 PM
#4801
Someone whose confident in this stock? Arnold25764 08/19/2022 08:25:26 PM
#4800
A Management insider.....again. m1ocha 08/19/2022 04:41:53 PM
#4799
Who the fuck bought 2 million shares? MASTERULTRA 08/19/2022 04:28:02 PM
#4798
Nice sized slaps now PStockPickz 08/19/2022 04:24:14 PM
#4797
It's typical arca stacks the close PStockPickz 08/19/2022 04:14:20 PM
#4796
They worked overtime to keep this thing down Odiwon 08/19/2022 04:07:32 PM
#4795
Awesome PStockPickz 08/19/2022 03:54:46 PM
#4794
Told y'all. m1ocha 08/19/2022 03:54:42 PM
#4793
Another form 4 filed. 300K bought around benchman 08/19/2022 03:53:55 PM
#4792
Finally moving. New HOD made. AH benchman 08/19/2022 03:50:18 PM
#4791
Dude hahahah that you? PStockPickz 08/19/2022 03:47:27 PM
#4790
Hope so. Fingers crossed PStockPickz 08/19/2022 03:40:35 PM
#4789
This will move up AH for sure. m1ocha 08/19/2022 03:30:50 PM
#4788
Been adding today. Average .22 but lot of PStockPickz 08/19/2022 02:27:13 PM
#4787
Game that MM's/shorts play to cover. They m1ocha 08/19/2022 12:23:26 PM
#4786
As far as I’m concerned it’s acting just Odiwon 08/19/2022 12:21:58 PM
#4785
This has become "two tic" flippers paradise. m1ocha 08/19/2022 12:17:57 PM
#4784
I grabbed a chunk myself this morning Odiwon 08/19/2022 10:29:24 AM
#4783
I’ve been watching this room for a month Odiwon 08/19/2022 10:28:57 AM
#4782
Quiet here. Considering the inside buying. m1ocha 08/19/2022 09:57:00 AM
#4781
No brainer. In for large chunk this m1ocha 08/19/2022 09:39:17 AM
#4780
This shows tremendous trust in the company. Odiwon 08/18/2022 11:58:27 PM
#4779
Hmm what do they know that the insiders trendzone 08/18/2022 04:25:15 PM
#4778
“Insider Shawn Singh reports buying 600,000 shares of StockLogistics 08/18/2022 04:17:40 PM
#4777
Looks like they are running out of shares StockLogistics 08/18/2022 10:23:17 AM
#4776
Chart says Tuesday opportunity, hopefully the Biostat is fast StockLogistics 08/17/2022 09:53:27 PM
#4775
This is somewhat true. The efficacy was ksviking12 08/14/2022 11:56:22 AM
#4774
“While we examine the results of our PALISADE-1 StockLogistics 08/14/2022 09:32:02 AM
#4773
Seems to be gaining momentum ahead of the Odiwon 08/11/2022 01:56:01 AM
Post Subject